Scottish deep-tech company Chemify has received £22 million ($29.7 million) in grants from Scottish Enterprise and the UK Government. The funding will support a significant expansion of Chemify’s capacity to digitise molecular discovery, synthesis and scale-up through a new Chemifarm. The grant package includes £16… Read More
Roche and Dualitas Therapeutics have announced a research collaboration and license agreement to advance novel bispecific antibodies for immunology & inflammation (I&I) diseases. Under the terms of the agreement, Dualitas will receive $36.5 million upfront payment and may receive additional research, development and commercial milestone payments for… Read More
A new company founded by Deep Science Ventures veterans has closed a £1.5 million (~$2m) pre-seed round and secured £700,000 (~$950K) Innovate UK funding. Big Picture Bio has been founded to identify, design and optimise promising cancer combination therapies, using a generative world model to understand how… Read More
Circio Holding has successfully completed a private placement raising gross proceeds to the company of approx. NOK 200 ($21) million, through the allocation of 16,865,000 new shares. The Offer Price corresponds to a 9% discount to the volume weighted average share price (VWAP) quoted for trade in… Read More
AI start-up deepmirror has been awarded a Phase 2 Sovereign AI grant as part of Innovate UK’s support for British businesses building world-leading AI technologies. The grant will fund deepmirror’s data acquisition strategy in which it selects the experiments most likely to improve its molecular… Read More
Revvity has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specialising in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases. The acquisition is expected to add HCD’s human pancreatic beta cell models to Revvity’s… Read More
Ratio Therapeutics and RayzeBio have entered into a research collaboration and license agreement to advance a novel radiopharmaceutical programme focused on two undisclosed targets. Under the terms of the agreement, Ratio will receive an upfront payment and is eligible to receive development, regulatory and commercial milestone payments,… Read More
CONNECTA Therapeutics has closed a €3.1 million financing led by new investor Clave Capital through its Innvierte Science Tech Clave Innohealth, FCR fund. The funds will support CONNECTA in accelerating the Phase IIa clinical trial of CTH120 in adult males with Fragile X syndrome (FXS). … Read More
Six promising companies will receive additional funding of €1.3 ($1.5) million each from BioInnovation Institute (BII) to help them bring their technologies and products closer to market. The six companies – PanTarg, 3Sonic, Inia Biosciences, Yngvi Bio, Proxi Biotech and Sagava – have all previously received €0.5… Read More
The Association of the British Pharmaceutical Industry’s (ABPI’s) 2026 flagship Competitiveness Report finds the UK has begun to reverse years of decline. However, the Association cautions that sustained delivery of government commitments will now determine whether the recovery holds. Since September 2025, the global pharmaceutical… Read More
Gan & Lee Pharmaceuticals and Menarini have announced plans to collaborate on the registration and commercialisation of Gan & Lee’s glucagon-like peptide-1 receptor agonist (GLP-1 RA) bofanglutide. The drug is under development for the treatment of adults with obesity or overweight, administered once every two weeks. … Read More
Eli Lilly has announced plans to acquire Merida Biosciences, a biotechnology company advancing a new class of precision therapeutics for serious autoimmune and allergic diseases. Merida is developing biologics engineered to selectively degrade pathogenic autoantibodies, the disease-causing agents behind a range of immune-mediated conditions. The… Read More
Roche has acquired exclusive global rights to develop, manufacture, and commercialise SIM0660, a trispecific antibody targeting CD79a, CD19, and CD3, with therapeutic potential across B-cell-mediated diseases. Under the terms of the agreement, developer Simcere Zaiming is eligible to receive up to $1.530 billion in total payments, including… Read More
Evotec and Plectonic Biotech have announced a research collaboration to explore a novel immunotherapy approach for solid tumours. The collaboration aims to address key challenges that have so far limited the successful application of traditional T cell engager therapies in solid tumours by combining Plectonic’s programmable LOGIBODY… Read More
Biohaven and SK Biopharmaceuticals have agreed a strategic global licensing and collaboration agreement under which SK Biopharmaceuticals will obtain an exclusive worldwide license to Biohaven’s Kv7 ion channel platform. The platform is led by opakalim (BHV-7000), a next-generation, selective Kv7.2/7.3 potassium channel activator in Phase II/III development… Read More
Revier Therapeutics has closed a €6 ($6.9) million seed financing and the launch of its operations. The company has established the first therapeutic approach to selectively target class IIa histone deacetylases (HDACs) for the treatment of cardiometabolic diseases. The financing was led by the KHAN… Read More
